FDA.reportPublic FDA data

antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl 1 UNT Injection

RxCUI
2631088
RxNorm name
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl 1 UNT Injection
Display name
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl 1 UNT Injection
Full name
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl 1 UNT Injection
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:45

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125771ALTUVIIIOantihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl351(a)Rx2026-06-01

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
01411972-df40-4ccf-88f0-d3220e5abda9antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl 1 UNT InjectionPSN10These highlights do not include all the information needed to use ALTUVIIIO ® safely and effectively. See full prescribing information for ALTUVIIIO. ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl], lyophilized powder for solution, for intravenous use Initial U.S. Approval: 202320260223
01411972-df40-4ccf-88f0-d3220e5abda9antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl 1 UNT InjectionSY10These highlights do not include all the information needed to use ALTUVIIIO ® safely and effectively. See full prescribing information for ALTUVIIIO. ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl], lyophilized powder for solution, for intravenous use Initial U.S. Approval: 202320260223
01411972-df40-4ccf-88f0-d3220e5abda9antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl 1 UNT InjectionSCD10These highlights do not include all the information needed to use ALTUVIIIO ® safely and effectively. See full prescribing information for ALTUVIIIO. ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl], lyophilized powder for solution, for intravenous use Initial U.S. Approval: 202320260223